Neurotoxicity Research

, Volume 21, Issue 2, pp 143–148 | Cite as

Effect of Pre- and Postnatal Manganese Exposure on Brain Histamine Content in a Rodent Model of Parkinson’s Disease

  • Ryszard Brus
  • Jerzy Jochem
  • Przemysław Nowak
  • Marta Adwent
  • Dariusz Boroń
  • Halina Brus
  • Richard M. Kostrzewa
Article

Abstract

Rats lesioned shortly after birth with 6-hydroxydopamine (6-OHDA; 134 μg icv) represent a near-ideal model of severe Parkinson’s disease because of the near-total destruction of nigrostriatal dopaminergic fibers. There are scarce data that in Parkinson’s disease, activity of the central histaminergic system is increased. The element manganese, an essential cofactor for many enzymatic reactions, itself in toxic amount, replicates some clinical features similar to those of Parkinson’s disease. The aim of this study was to examine the effect of neonatal manganese exposure on 6-OHDA modeling of Parkinson’s disease in rats, and to determine effects on histamine content in the brain of these rats in adulthood. Manganese (MnCl2·4H2O; 10,000 ppm) was included in the drinking water of pregnant Wistar rats from the time of conception until the 21st day after delivery, the age when neonatal rats were weaned. Control rats consumed tap water. Other groups of neonatal rat pups, on the 3rd day after birth, were pretreated with desipramine (20 mg/kg ip 1 h) prior to bilateral icv administration of 6-OHDA (60 or 134 μg) or its vehicle saline–ascorbic (0.1%) (control). At 2 months after birth, in rats lesioned with 60 or 134 μg 6-OHDA, endogenous striatal dopamine (DA) content was reduced, respectively, by 92 and 98% (HPLC/ED), while co-exposure of these groups to perinatal manganese did not magnify the DA depletion. However, there was prominent enhancement of histamine content in frontal cortex, hippocampus, hypothalamus, and medulla oblongata of adult rat brain after 6-OHDA (60 and 134 μg) injection on the day 3rd postnatal day. These findings indicate that histamine and the central histaminergic system are altered in the brain of rats lesioned to model Parkinson’s disease, and that manganese enhances effects of 6-OHDA on histamine in brain.

Keywords

Manganese 6-Hydroxydopamine Histamine Brain Rats 

References

  1. Ali SF, Duhart HM, Newport GD, Lipe GW, Slikker W Jr (1995) Manganese-induced reactive oxygen species: comparison between Mn+2 and Mn+3. Neurodegeneration 2:329–334CrossRefGoogle Scholar
  2. Anichtchik OV, Rinne J, Kalimo H, Panula P (2000) An altered histaminergic innervation of the substantia nigra in Parkinson’s disease. Exp Neurol 163:20–30PubMedCrossRefGoogle Scholar
  3. Archibald FS, Tyre C (1987) Manganese poisoning and the attack of trivalent manganese upon catecholamines. Arch Biochem Biophys 256:638–650PubMedCrossRefGoogle Scholar
  4. Aschner M, Kimelberg HK (1996) Astrocytes: potential modulators of heavy metal-induced neurotoxicity. In: Chang LW (ed) Toxicology of metals. Lewis Publisher, London, pp 587–608Google Scholar
  5. Barceloux DG (1999) Manganese. Clin Toxicol 37:293–307CrossRefGoogle Scholar
  6. Berger TW, Kaul S, Stricker EM, Zigmond MJ (1985) Hyperinnervation of the striatum by dorsal raphe afferents after dopamine-depleting brain lesions in neonatal rats. Brain Res 336:354–358PubMedCrossRefGoogle Scholar
  7. Bouchard M, Laforest F, Vandelac L, Bellinger D, Mergler D (2007) Hair manganese and hyperactive behaviors: pilot study of school-age children exposed through tap water. Environ Health Perspect 115:122–127PubMedCrossRefGoogle Scholar
  8. Brus R, Kostrzewa RM, Perry KW, Fuller RW (1994) Supersensitization of the oral response to SKF 38393 in neonatal 6-hydroxydopamine-lesioned rats is eliminated by neonatal 5,7-dihydroxytryptamine treatment. J Pharmacol Exp Ther 260:231–237Google Scholar
  9. Brus R, Nowak P, Sokoła A, Labus L, Oswicimska J, Winiarska H, Kostrzewa RM, Shani J (2002a) Exposure of pregnant rats to manganese: effect on levels, turnover and release of biogenic amines in brains of their offspring. Pharmacol Rev Commun 12:61–75CrossRefGoogle Scholar
  10. Brus R, Szkilnik R, Konecki J, Stepien M, Malecki S, Kuballa G, Mengel K, Shani J (2002b) Prenatal exposure of rats to manganese: changes in reactivity of their central dopaminergic, serotoninergic and muscrine receptors, but not of glucose uptake in their adult offsprings. Pharmacol Rev Commun 12:9–24CrossRefGoogle Scholar
  11. Calne DB, Chu NS, Huang CC, Lu CS, Olanow W (1994) Mechanism and idiopathic parkinsonism: similarities & differences. Neurology 44:1583–1586PubMedGoogle Scholar
  12. Chan AW, Minski MJ, Lim L, Lai JC (1992) Changes in brain regional during postnatal development: modulations by chronic manganese administration. Met Brain Dis 7:21–33CrossRefGoogle Scholar
  13. Chandra SV, Shukla GS, Srivastava RS, Singh H, Gupta VP (1981) Exploratory study of manganese exposure to welders. Clin Toxicol 18:407–416PubMedCrossRefGoogle Scholar
  14. Cochlo MH, Silva IJ, Azevedo MS, Manso CF (1991) Decrease in blood histamine in drug-treated Parkinsonian patients. Mol Chem Neuropathol 14:77–85CrossRefGoogle Scholar
  15. Cook DG, Fahn S, Brait KA (1974) Chronic manganese intoxication. Arch Neurol 30:59–64PubMedCrossRefGoogle Scholar
  16. Cotzias GC, Papavasilion PS, Ginos J, Stechk A, Duby S (1971) Metabolic modification of Parkinson’s disease and chronic manganese poisoning. Annu Rev Med 22:305–336PubMedCrossRefGoogle Scholar
  17. Davids E, Zhang K, Tarazi FI, Baldessarini RJ (2003) Animal models of attention-deficit hyperactivity disorder. Brain Res Brain Res Rev 42:1–21PubMedCrossRefGoogle Scholar
  18. Davidson L, Cederblad A, Lonnerdal B, Sandstrom B (1989) Manganese absorption from human milk, cow’s milk and infant formulas in humans. Am J Dis Child 143:823–827Google Scholar
  19. Desole MS, Esposito G, Migheli R, Fresu L, Sireana S, Miele M, De-Natale G, Miele E (1995) Allopurinol protects against manganese-induced oxidative stress in striatum and in the brainstem of the rat. Neurosci Lett 192:73–76PubMedCrossRefGoogle Scholar
  20. Donaldson J (1987) The physiopathologic significance of manganese in brain: its relation to schizophrenia and neurodegenerative disorders. Neurotoxicology 8:451–462PubMedGoogle Scholar
  21. Farias AC, Cunha A, Benko CR, McCracken JT, Costa MT, Farias LG, Cordeiro ML (2010) Manganese in children with attention-deficit/hyperactivity disorder: relationship with methylphenidate exposure. J Child Adolesc Psychopharmacol 20:113–118PubMedCrossRefGoogle Scholar
  22. Gennart JP, Buchet JP, Roels H, Ghyselen P, Ceulemans E, Lauwerys R (1992) Fertility of male workers exposed to cadmium, lead, or manganese. Am J Epidemiol 135:1208–1219PubMedGoogle Scholar
  23. Ingersoll RT, Montgomery EBJr, Aposhian HV (1995) Central nervous system toxicity of manganese. I. Inhibition of spontaneous motor activity in rats after intrathecal administration of manganese chloride. Fundam Appl Toxicol 27:106–113PubMedCrossRefGoogle Scholar
  24. Inoue N, Makita Y (1996) Neurological aspects in human exposure to manganese. In: Chang LW (ed) Toxicology of metals. Lewis Publisher, London, pp 415–438Google Scholar
  25. Jochem J (2004) Involvement of the sympathetic nervous system in the reversal of critical haemorrhacic hypotension by endogenous central histamine in rats. Naunyn Schmiedebergs Arch Pharmacol 369:418–427PubMedCrossRefGoogle Scholar
  26. Kontur PJ, Fechter LD (1985) Brain manganese, catecholamine turnover and the development of startle in rats prenatally exposed to manganese. Teratology 32:1–11PubMedCrossRefGoogle Scholar
  27. Kontur PJ, Fechter LD (1988) Brain manganese, catecholamine turnover, and the development of startle in rats prenatally exposed to manganese. Neurotoxicol Teratol 10:295–303PubMedCrossRefGoogle Scholar
  28. Kostrzewa RM (2001) Mechanism of action of 6-hydroxydopamine, a dopaminergic neurotoxin. In: Segura-Aguilar J (ed) Mechanisms of degeneration and protection of the dopaminergic system. FP Graham Publishing Co., Johnson, pp 89–104Google Scholar
  29. Kostrzewa RM, Gong L, Brus R (1992) Serotonin (5-HT) systems mediate dopamine (DA) receptor supersensitivity. Acta Neurobiol Exp 53:31–41Google Scholar
  30. Kostrzewa RM, Brus R, Kalbfleisch JH, Perry KW, Fuller RW (1994) Proposed animal model of attention deficit hyperactivity disorder. Brain Res Bull 34:161–167PubMedCrossRefGoogle Scholar
  31. Kostrzewa RM, Reader TA, Descarries L (1998) Serotonin neural adaptations to ontogenetic loss of dopamine neurons in rat brain. J Neurochem 70:889–898PubMedCrossRefGoogle Scholar
  32. Kostrzewa RM, Kostrzewa JP, Brus R, Kostrzewa RA, Nowak P (2006) Proposed animal model of severe Parkinson’s disease: neonatal 6-hydroxydopamine lesion of dopaminergic innervation of striatum. J Neural Transm Suppl 70:277–279PubMedCrossRefGoogle Scholar
  33. Kostrzewa RM, Kostrzewa JP, Kostrzewa RA, Nowak P, Brus R (2007) Pharmacological models of ADHD. J Neural Transm 115:287–298PubMedCrossRefGoogle Scholar
  34. Lai JC, Leung TK, Lim L, Chan AW, Minski MJ (1991) Effect of chronic manganese treatment on rat brain regional sodium-potassium-activated and magnesium-activated adenosine-triphosphatase activities during development. Metab Brain Dis 6:165–174PubMedCrossRefGoogle Scholar
  35. Liu LL, Yang J, Lei GF, Wang GJ, Wang YW, Sun RP (2008) Atomoxetine increases histamine release and improves learning deficits in an animal model of attention-deficit hyperactivity disorder: the spontaneously hypertensive rat. Basic Clin Pharmacol Toxicol 102:527–532PubMedCrossRefGoogle Scholar
  36. Magnusson O, Nilsson LB, Westerland D (1980) Simultaneous determination of dopamine, DOPAC and homovanillic acid. Direct injection of supernatansts from brain tissue homogenates in a liquid chromatography–electrochemical detection system. J Chromatogr 221:237–247PubMedCrossRefGoogle Scholar
  37. Mena I, Marin O, Fuenzalida S, Cotzias GC (1967) Chronic manganese poisoning. Clinical picture and manganese turnover. Neurology 17:128–136PubMedGoogle Scholar
  38. Mena I, Kazuko H, Burke K, Cotzias GC (1969) Chronic manganese poisoning: individual susceptibility and absorption of iron. Neurology 19:1000–1006PubMedGoogle Scholar
  39. Mendes-Alvares E, Soto-Otero R, Hermida-Ameijeiras A, Lopez-Martin ME (2001) Effect of iron and manganese on hydroxyl radical production by 6-hydroxydopamine: mediation of antioxidants. Free Radic Biol Med 31:986–998CrossRefGoogle Scholar
  40. Nowak P, Noras Ł, Jochem J, Szkilnik R, Brus H, Korossy E, Drab J, Kostrzewa RM, Brus R (2009) Histaminergic activity in a rodent model of Parkinson’s disease. Neurotox Res 15:246–251PubMedCrossRefGoogle Scholar
  41. Nowak P, Bojanek K, Szkilnik R, Jośko J, Boroń D, Adwent M, Gorczyca P, Kostrzewa RM, Brus R (2011) Ontogenetic exposure of rats to pre- and post-natal manganese enhances behavioral impairments produced by perinatal 6-hydroxydopamine. Neurotox Res 19(4):536–543PubMedCrossRefGoogle Scholar
  42. Panula P, Airaksinen MS, Pirvola U, Kotilainen E (1990) A histamine-containing neuronal system in human brain. Neuroscience 34:127–132PubMedCrossRefGoogle Scholar
  43. Pentschew W, Ebner FF, Koratch RM (1963) Experimental manganese encephalopathy in monkeys. J Neuropathol Exp Neurol 22:488–499PubMedCrossRefGoogle Scholar
  44. Prell GD, Green JP (1991) Histamine metabolites and pros-methylimidazoleacetic acid in human cerebrospinal fluid. Agents Actions Suppl 33:343–363PubMedCrossRefGoogle Scholar
  45. Rinne JO, Aniehtchik OV, Errikson KS, Kaslin L, Tuomisto L, Kalimo H, Röytta M, Panula P (2002) Increase brain histamine levels in Parkinson’s disease but not in multiple system atrophy. J Neurochem 81:954–960PubMedCrossRefGoogle Scholar
  46. Rodier J (1955) Manganese poisoning in Moroccan miners. Br J Ind Med 12:21–35PubMedGoogle Scholar
  47. Schwartz JC, Arrang JM, Garbarg M, Pollard H, Rant M (1991) Histaminergic transmission in the mammalian brain. Physiol Rev 71:1–51PubMedGoogle Scholar
  48. Seth PK, Husain R, Mishtag M, Chandro SV (1997) Effect of manganese on neonatal rat: manganese concentration and enzymatic alterations in brain. Acta Pharmacol Toxicol 40:553–560Google Scholar
  49. Shaywitz BA, Yager RD, Klopper JH (1976) Selective brain dopamine depletion in developing rats: an experimental model of minimal brain dysfunction. Science 191:305–308PubMedCrossRefGoogle Scholar
  50. Sloot WN, Gramsbergen JB (1994) Axonal transport of manganese and its relevance to selective neurotoxicity in the rat basal ganglia. Brain Res 657:124–132PubMedCrossRefGoogle Scholar
  51. Sloot WN, van der Sluijs-Gelling AJ, Gramsbergen JB (1994) Selective lesions by manganese and extensive damage by iron after injection into rat striatum or hippocampus. J Neurochem 62:205–216PubMedCrossRefGoogle Scholar
  52. Sloot WN, Korf J, Koster JF, De Wit LE, Gramsbergen JB (1996) Manganese-induced hydroxyl radical formation in rat striatum is not attenuated by dopamine depletion. Exp Neurol 138:236–245PubMedCrossRefGoogle Scholar
  53. Snyder AM, Zigmond MJ, Lund RD (1986) Sprouting of serotoninergic afferents into striatum after dopamine-depleting lesions in infant rats: a retrograde transport and immunocytochemical study. J Comp Neurol 245:274–281PubMedCrossRefGoogle Scholar
  54. Tanaka S, Lieben J (1969) Manganese poisoning and exposure in Pennsylvania. Arch Environ Health 19:647–684Google Scholar
  55. Tarohda T, Ishida Y, Kawai K, Yamamoto M, Amano R (2005) Regional distributions of manganese, iron, copper and zinc in the brains of 6-hydroxydopamine-induced parkinsonian rats. Anal Bioanal Chem 383:224–234PubMedCrossRefGoogle Scholar
  56. Wada H, Inagaki N, Itowi N, Yamatodani A (1991) Histaminergic neuron system in the brain: distribution and possible functions. Brain Res Bull 27:367–370PubMedCrossRefGoogle Scholar
  57. Wagner J, Vitali P, Palfreyman MG, Zraika M, Hout S (1982) Simultaneous determination of 3,4-dihydroxyphenylalanine, 5-hydroxytryptophan, dopamine, 4-hydroxy-3-MPA, NE, 3,4-dihydroxyphenylacetic acid, homovanillic acid, serotonin, and 5-HIAA in rat cerebrospinal fluid and brain by HPLC. J Neurochem 38:1241–1254PubMedCrossRefGoogle Scholar
  58. Witholt R, Gwiazda RH, Smith DR (2000) The neurobehavioral effects of subchronic manganese exposure in the presence and absence of pre-parkinsonism. Neurotox Teratol 22:851–861CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Ryszard Brus
    • 1
    • 2
  • Jerzy Jochem
    • 3
  • Przemysław Nowak
    • 1
    • 2
  • Marta Adwent
    • 1
    • 2
  • Dariusz Boroń
    • 3
  • Halina Brus
    • 3
  • Richard M. Kostrzewa
    • 4
  1. 1.Department of PharmacologyMedical University of SilesiaZabrzePoland
  2. 2.Department of NurseHigh School of Strategic PlanningDąbrowa GórniczaPoland
  3. 3.Department of Basic Medical SciencesMedical University of SilesiaBytomPoland
  4. 4.Department of Pharmacology, Quillen College of MedicineEast Tennessee State UniversityJohnsonUSA

Personalised recommendations